Wang Ke, Luo Jun, Zheng Limin, Luo Tao
Department of Anesthesiology, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen, 518036, Guangdong, People's Republic of China.
Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, People's Republic of China.
J Anesth. 2017 Dec;31(6):852-860. doi: 10.1007/s00540-017-2409-0. Epub 2017 Sep 21.
Non-steroidal anti-inflammatory drugs have been shown to effectively decrease postoperative pain and reduce opioid requirements. Flurbiprofen axetil is an injectable non-selective cyclooxygenase inhibitor that has a high affinity for inflammatory tissues to achieve targeted drug therapy and prolonged duration of action. This meta-analysis examined the use of preoperative flurbiprofen axetil and its impact on postoperative analgesia.
An electronic literature search of the Library of PubMed, Cochrane CENTRAL, and EMBASE databases was conducted in Feb 2016. Searches were limited to randomized controlled trials. The primary outcome was pain scores. The secondary outcomes included cumulative postoperative opioid consumption and opioid-related adverse effects.
A total of nine RCT studies involving 457 patients were included in this study. Compared to patients without perioperative flurbiprofen axetil, patients treated with preoperative flurbiprofen axetil had lower pain scores at 2 h (SMD -1.00; 95% CI -1.57 to -0.43, P = 0.0006), 6 h (SMD -1.22; 95% CI -2.01 to -0.43; P = 0.002), 12 h (SMD -1.19; 95% CI -2.10 to -0.28; P = 0.01), and 24 h (SMD -0.79; 95% CI -1.31 to -0.27; P = 0.003) following surgery. Preoperative flurbiprofen axetil had no significant effect on postoperative opioid consumption (SMD -13.11; 95% CI -34.56 to 8.33; P = 0.23). There was no significant difference between the groups with regard to adverse effects. Compared to patients with postoperative flurbiprofen axetil, however, preoperative flurbiprofen axetil resulted in decreased pain score only at 2 h after operation.
Preoperative use of flurbiprofen axetil will result in significantly lower postoperative pain scores, but no difference in nausea, vomiting, and opioid consumption compared to those who did not receive flurbiprofen axetil. However, more homogeneous and well-designed clinical studies are necessary to determine whether preoperative flurbiprofen axetil administration has more efficacy than that given at the end of surgery.
非甾体类抗炎药已被证明可有效减轻术后疼痛并减少阿片类药物的用量。氟比洛芬酯是一种注射用非选择性环氧化酶抑制剂,对炎症组织具有高亲和力,可实现靶向药物治疗并延长作用时间。本荟萃分析研究了术前使用氟比洛芬酯及其对术后镇痛的影响。
2016年2月对PubMed图书馆、Cochrane CENTRAL和EMBASE数据库进行了电子文献检索。检索限于随机对照试验。主要结局为疼痛评分。次要结局包括术后阿片类药物累计用量及阿片类药物相关不良反应。
本研究共纳入9项随机对照试验研究,涉及457例患者。与未围手术期使用氟比洛芬酯的患者相比,术前使用氟比洛芬酯治疗的患者在术后2小时(标准化均数差-1.00;95%置信区间-1.57至-0.43,P = 0.0006)、6小时(标准化均数差-1.22;95%置信区间-2.01至-0.43;P = 0.002)、12小时(标准化均数差-1.19;95%置信区间-2.10至-0.28;P = 0.01)和24小时(标准化均数差-0.79;95%置信区间-1.31至-0.27;P = 0.003)的疼痛评分更低。术前使用氟比洛芬酯对术后阿片类药物用量无显著影响(标准化均数差-13.11;95%置信区间-34.56至8.33;P = 0.23)。两组在不良反应方面无显著差异。然而,与术后使用氟比洛芬酯的患者相比,术前使用氟比洛芬酯仅在术后2小时导致疼痛评分降低。
术前使用氟比洛芬酯将导致术后疼痛评分显著降低,但与未接受氟比洛芬酯的患者相比,在恶心、呕吐和阿片类药物用量方面无差异。然而,需要更同质且设计良好的临床研究来确定术前给予氟比洛芬酯是否比手术结束时给予更有效。